Novo Nordisk: Langzeitdaten überzeugen – Aktie zeigt Stärke
Novo Nordisk hat auf einem Kongress in Paris neue Daten zu seinen Hämophilie-Programmen vorgestellt. Im Fokus stand die laufende Phase-3-Verlängerungsstudie FRONTIER4 zu Denecimig (Mim8) zur…
Read the full articlede
You might also wanna read
Who May Face Income Tax Scrutiny in FY 2026-27? CBDT Issues Fresh Guidelines for Complete Scrutiny
Sahi·just now
Experts split on Brazil’s response to new U.S. tariffs
revistaquem.globo.com·4m ago
Ghana: Volta Economic Corridor Will Be One of Ghana’s Most Strategic Growth Corridors — President Mahama
Zawya·20m ago
Krypto News: Coinbase-CEO Armstrong möchte Aktien für Alle
Coincierge.de·24m ago
Eve, Hitachi Energy partner on eVTOL charging infrastructure
revistaquem.globo.com·28m ago
Portugal seeks Brazilian investment in biofuels, SAF production
revistaquem.globo.com·28m ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.